Every 424B that Biohaven Ltd. (BHVN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BHVN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BHVN filings page.
Biohaven Ltd. is offering common shares having an aggregate offering price of up to $350,000,000 through an amendment dated May 4, 2026 to its equity distribution agreement with J.P. Morgan Securities LLC. The shares will be sold as at-the-market offerings from time to time. The company reported 150,506,490 common shares outstanding as of March 31, 2026. Sales may occur in ordinary brokers’ transactions, to or through market makers, on the NYSE or other permitted venues, and the sales agent may act as agent or principal. The sales agent may receive up to 3.00% of gross proceeds as compensation.
Biohaven Ltd. (BHVN) is offering 23,333,334 common shares at $7.50 per share in a primary offering. The deal totals $175,000,005 before fees, with underwriting discounts of $0.45 per share. The company estimates net proceeds of approximately $164.0 million and plans to use the funds for general corporate purposes.
The underwriters have a 30‑day option to buy up to 3,500,000 additional shares. Common shares outstanding are expected to be 129,136,989 immediately after the offering, or 132,636,989 if the option is fully exercised. Certain insiders, including the CEO, have indicated interest in purchasing about $60,000,000 of shares, with $5,000,000 indicated by the CEO; these indications are not binding. A 30‑day lock‑up applies to the company and to directors and officers. BHVN trades on the NYSE; the last reported sale was $8.52 on November 11, 2025.
Biohaven Ltd. is conducting a $150,000,000 primary offering of common shares pursuant to a prospectus supplement. The deal includes a 30‑day option for underwriters to purchase additional shares after pricing.
The company expects to use net proceeds for general corporate purposes. Insider interest is indicated at approximately $60,000,000 in aggregate, including about $5,000,000 from the CEO, subject to allocation by underwriters. Biohaven’s common shares trade on the NYSE under “BHVN”; the last reported price was $7.79 on November 10, 2025.
As context, 105,803,655 common shares were outstanding as of September 30, 2025; this is a baseline figure, not the amount being offered. The company has a 30‑day lock‑up, and directors and officers are subject to similar lock‑ups, with customary exceptions described under “Underwriting.”